Literature DB >> 3493690

Neoplastic complications of HTLV-III infection. Lymphomas and solid tumors.

M H Kaplan, M Susin, S G Pahwa, J Fetten, S L Allen, S Lichtman, M G Sarngadharan, R C Gallo.   

Abstract

Neoplastic disease arose in 29 of 200 patients infected with human T lymphotropic virus type III (HTLV-III) seen at a suburban hospital. Seventeen patients had Kaposi's sarcoma, one of whom also had colon carcinoma. Nine patients had lymphoproliferative disorders (seven lymphomas, one T suppressor cell chronic lymphocytic leukemia, and one multiple myeloma), including three with concomitant Kaposi's sarcoma and one with colon cancer. One other patient had colon cancer, one had a seminoma, and one had pancreatic cancer. Kaposi's sarcoma as a complication of AIDS occurred mainly in homosexuals (17 of 42 homosexuals, one of 17 drug abusers, one of five heterosexually promiscuous patients, and one of six patients who had previously received transfusions). The high-grade lymphomas did not show a predilection for any particular AIDS risk group. Three of four solid tumors arose in elderly AIDS patients. Twenty-five of 75 patients with CDC-defined AIDS had a neoplastic disorder (26 are still alive and may yet demonstrate malignancy). Few other diseases of man have been associated with as high an incidence of neoplastic transformation as occurs with HTLV-III infection.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3493690     DOI: 10.1016/0002-9343(87)90435-9

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  9 in total

1.  Non-acquired immune deficiency syndrome-defining malignancies in a hospital-based cohort of human immunodeficiency virus-infected patients: Bordeaux, France, 1985-1991. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.

Authors:  M Hajjar; D Lacoste; G Brossard; P Morlat; M Dupon; L R Salmi; F Dabis
Journal:  J Natl Cancer Inst       Date:  1992-10-21       Impact factor: 13.506

2.  Impact of the human immunodeficiency virus epidemic on mortality trends in young men, United States.

Authors:  J W Buehler; O J Devine; R L Berkelman; F M Chevarley
Journal:  Am J Public Health       Date:  1990-09       Impact factor: 9.308

3.  HIV-related non-Hodgkin's lymphoma in Calgary.

Authors:  P L Beck; M J Gill; W B Blahey; L R Sutherland
Journal:  Can J Infect Dis       Date:  1996-03

4.  Down-regulation of membrane immunoglobulin-associated proteins, MB-1, B29 and Lyn, in AIDS-lymphomas and related conditions.

Authors:  S Mori; M Takanashi; M Shiota; S H Choi; Y Yamanashi; T Watanabe; M Koike
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

5.  Gastric manifestations of AIDS: radiographic findings on upper gastrointestinal examination.

Authors:  S Falcone; B J Murphy; A Weinfeld
Journal:  Gastrointest Radiol       Date:  1991

6.  Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation.

Authors:  B Ensoli; L Buonaguro; G Barillari; V Fiorelli; R Gendelman; R A Morgan; P Wingfield; R C Gallo
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

7.  Treatment of chronic lymphocytic leukemia with bendamustine in an HIV-infected patient on antiretroviral therapy: a case report and review of the literature.

Authors:  Naoki Shimada; Koichiro Yuji; Nobuhiro Ohno; Tomohiko Koibuchi; Naoki Oyaizu; Kaoru Uchimaru; Arinobu Tojo
Journal:  Clin Case Rep       Date:  2015-04-22

Review 8.  Second neoplasms in patients with chronic lymphocytic leukemia.

Authors:  Peter H Wiernik
Journal:  Curr Treat Options Oncol       Date:  2004-06

9.  IL-22 receptor signaling in Paneth cells is critical for their maturation, microbiota colonization, Th17-related immune responses, and anti-Salmonella immunity.

Authors:  Stephen J Gaudino; Michael Beaupre; Xun Lin; Preet Joshi; Sonika Rathi; Patrick A McLaughlin; Cody Kempen; Neil Mehta; Onur Eskiocak; Brian Yueh; Richard S Blumberg; Adrianus W M van der Velden; Kenneth R Shroyer; Agnieszka B Bialkowska; Semir Beyaz; Pawan Kumar
Journal:  Mucosal Immunol       Date:  2020-10-15       Impact factor: 8.701

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.